Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
IPO Year: 2011
Exchange: NASDAQ
Website: pacira.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | $30.00 → $8.00 | Buy → Sell | Truist |
| 8/12/2024 | $42.00 → $11.00 | Overweight → Neutral | Piper Sandler |
| 8/12/2024 | $45.00 → $10.00 | Overweight → Underweight | JP Morgan |
| 8/12/2024 | Outperform → Mkt Perform | Raymond James | |
| 8/12/2024 | $37.00 → $14.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/3/2024 | $38.00 → $25.00 | Overweight → Equal Weight | Barclays |
| 3/7/2024 | $80.00 → $45.00 | Overweight | JP Morgan |
| 12/20/2023 | $42.00 | Outperform | Raymond James |
| 8/3/2023 | $50.00 | Market Perform → Outperform | TD Cowen |
| 1/31/2023 | $88.00 → $60.00 | Outperform | Wedbush |
PARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth-oriented plan to accelerate its ongoing transition into an innovative biopharmaceutical organization and become a therapeutic area leader in musculoskeletal pain and adjacencies. In addition, the company reported preliminary unaudited total revenue of $701.0 million for the year ended December 31, 2024, compared with $675.0 million for the year ended December 31, 2023. 5x30 Path to growth and value creation The company intends to achiev
PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market a new Smart Tip designed to access the medial branch nerves to manage chronic low back pain. The ioveraº system is an innovative, FDA-cleared, drug-free treatment that relieves pain via cryoneurolysis—a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals. Pain relief is typically experienced immediately afte
PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on Wednesday, January 15, 2025. Live audio of the event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About PaciraPacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently
Former CEO, Sander van Deventer to become President of R&D Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package Expansion of corporate footprint into the US (Boston) VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216441837/en/VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo
Expresses Conviction in Pacira's IP and Belief that Shares are Significantly Undervalued Urges Pacira to Immediately Commence Stock Tender Offer with Cash on Hand MIAMI, Dec. 11, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (together with its affiliates, "DOMA"), which beneficially owns approximately 4.14% of the outstanding shares of Common Stock of Pacira BioSciences, Inc. (NASDAQ:PCRX) ("Pacira" or the "Company"), today announced that it intends to nominate four highly-qualified, independent director candidates at the Company's 2025 annual meeting of stockholders, and stated that it has hired Olshan Frome Wolosky LLP as counsel to represent it in its dealings with the Compan
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors. Four employees received stock options to purchase an aggregate of 19,800 shares of Pacira common stock and the four employees received restricted stock units
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the ‘940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The ‘940 patent, entitled "Manufacturing of Bupivacaine Multivesicular Liposomes" protects the chemical composition of EXPAREL® (bupivacaine liposome injectable suspension). This patent is the first patent from a new family of patents related to EXPAREL produced by the
PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201 (enekinragene inzadenovec), provided sustained improvements in knee pain, stiffness, and function to 104 weeks following local administration, with a well-tolerated safety profile. The data, which indicate a potential for sustained clinical efficacy in patients with moderate to severe osteoarthritis of the knee (OAK), will be presented during a poster session at the American College of Rheumatol
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 19th at 3:00PM GMT (10:00AM ET).36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1:00PM ET. Live audio of the events can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events. About PaciraPacira BioSciences delivers innovative, non-opioid pain therapies to transform
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights Total revenues of $168.6 millionNet product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and $5.7 million for iovera°Net loss of $143.5 million, or $3.11 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.7 million See "Non-GAAP Financial Information" below. "2024 continues to be highligh
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights Total revenues of $168.6 millionNet product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and $5.7 million for iovera°Net loss of $143.5 million, or $3.11 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.7 million See "Non-GAAP Financial Information" below. "2024 continues to be highligh
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Paci
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2024. Second Quarter 2024 Financial Highlights Total revenues of $178.0 millionNet product sales of $136.9 million for EXPAREL, $30.7 million for ZILRETTA, and $5.7 million for iovera°Net income of $18.9 million, or $0.41 per share (basic) and $0.39 per share (diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $62.1 million See "Non-GAAP Financial Informatio
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira websit
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024. First Quarter 2024 Financial Highlights Total revenues of $167.1 millionNet product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°Net income of $9.0 million, or $0.19 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.6 million See "Non-GAAP Financial Information" below. "Sales are
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. To participate in the conference call, dial 1-800-715-9871 and provide the passcode 6363041. International callers may dial 1-646-307-1963 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com. About Pacira Pacira
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m. ET — TAMPA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2023. "Now that I have spent several weeks working with the Pacira team, I am even more enthusiastic to lead this great company as we build upon an impressive foundation of success," said Frank D. Lee, chief exec
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through
-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023. Third Quarter 2023 Financial Highlights Total revenues of $163.9 millionNet product sales of $128.7 million for EXPAREL, $28.8 million for ZILRETTA, and $5.3 million for iovera°Net income of $10.9 millio
TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday November 2, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira web
Former CEO, Sander van Deventer to become President of R&D Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package Expansion of corporate footprint into the US (Boston) VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216441837/en/VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r
-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately. "We are pleased to welcome these four highly seasoned executives to our Board of Directors, whose experience will enhance our board as we advance on our strategic objectives across multiple key areas," said Dave Stack, chairman and chief executive
David Stack to Retire as Chairman and CEO Once Successor is Appointed Board Has Initiated Search for Successor TAMPA, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that David ("Dave") Stack will retire from his role as Chairman and Chief Executive Officer. To ensure a seamless transition, Mr. Stack has committed to continuing in his current role until a new CEO is appointed by the board of directors, who are conducting the search. He will then continue in a consulting role with the company through August of 2025. "On behalf of our enti
TAMPA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointment of Christopher Young to the position of Chief Manufacturing Officer. Mr. Young will be responsible for oversight of all manufacturing activities across the Pacira product portfolio including supply chain design, product life cycle management, demand and requirements planning, capacity, and product launches across all global manufacturing locations. "Chris is a seasoned operations professional with strong and well-rounded manufacturing expertise, and a keen leadership ac
Mr. Scibetta is an accomplished biotech executive who brings over 20 years of experience successfully leading life science companies from early-stage platform development through major value-generating milestones ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, today announced the appointment of James S. Scibetta as Chief Executive Officer and a member of the Board of Directors. Mr. Scibetta succeeds David Donabedian, Ph.D., Venture Partner of Longwood Fund, who had been serving as CEO and will serve in an advisory capacity to the Company. This press release features mult
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
3 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
Truist downgraded Pacira BioSciences from Buy to Sell and set a new price target of $8.00 from $30.00 previously
Piper Sandler downgraded Pacira BioSciences from Overweight to Neutral and set a new price target of $11.00 from $42.00 previously
JP Morgan downgraded Pacira BioSciences from Overweight to Underweight and set a new price target of $10.00 from $45.00 previously
Raymond James downgraded Pacira BioSciences from Outperform to Mkt Perform
RBC Capital Mkts downgraded Pacira BioSciences from Outperform to Sector Perform and set a new price target of $14.00 from $37.00 previously
Barclays downgraded Pacira BioSciences from Overweight to Equal Weight and set a new price target of $25.00 from $38.00 previously
JP Morgan resumed coverage of Pacira BioSciences with a rating of Overweight and set a new price target of $45.00 from $80.00 previously
Raymond James initiated coverage of Pacira BioSciences with a rating of Outperform and set a new price target of $42.00
TD Cowen upgraded Pacira BioSciences from Market Perform to Outperform and set a new price target of $50.00
Wedbush resumed coverage of Pacira BioSciences with a rating of Outperform and set a new price target of $60.00 from $88.00 previously
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4/A - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
SCHEDULE 13G - Pacira BioSciences, Inc. (0001396814) (Subject)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)